RESULTS: Among 2439 patients, cumulative exposure was greatest for docetaxel (n¼1886 (77.3%); 11,436 person-months), followed by abiraterone (n¼893 (36.6%); 5143 person-months), enzalutamide (n¼52 (2.1%); 351 person-months) and cabazitaxel (n¼18 (0.7%); 61 person-months). Abiraterone exposure was not significantly associated with any-cause (HR 0.88, 95% CI 0.72-1.07) or treatment-related (HR 1.09, 95% CI 0.87-1.37) hospitalizations or ER visits. Enzalutamide was not significantly associated with anycause (HR 1.20, 95% CI 0.69-2.07) or treatment-related (HR 0.85, 95% CI 0.43-1.68) toxicity. Docetaxel exposure was associated with a significantly increased risk of any-cause (HR 1.29, 95% CI 1.15-1.44) and treatment-related (HR 1.52, 95% CI 1.33-1.74) toxicity. Cabazitaxel exposure was also associated with treatment-related (HR 5.94, 95% CI 1.87-18.92) but not any-cause (HR 2.37, 95% CI 0.59-9.63) toxicity. Patients who began CRPC treatment after the introduction of oral therapies had improved overall survival compared with those treated prior to their introduction (aHR 0.70, 95% CI 0.64-0.77).
INTRODUCTION AND OBJECTIVES: Radium-223 improved overall survival (OS) with meaningful improvements versus placebo in health-related quality of life (HRQoL) in phase 3 ALSYMPCA (Parker NEJM 2013; Nilsson Ann Oncol 2016) . We examined the relationship of OS to baseline HRQoL scores or change from baseline by prior docetaxel subgroup.
METHODS: HRQoL in ALSYMPCA was assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire at baseline, during treatment (wk 16, 24) , and during follow-up. Cox proportional hazards model for OS was fitted using HRQoL baseline scores and included previously identified covariates: treatment (radium-223 vs placebo); log 10 baseline lactate dehydrogenase, alkaline phosphatase, and prostate-specific antigen; age; baseline Eastern Cooperative Oncology Group performance status; and albumin. A time-dependent model also included change from baseline HRQoL scores. Results are presented by prior docetaxel subgroup.
RESULTS: The analysis included patients with baseline HRQoL scores: 466-485 patients with prior docetaxel and 354-362 with no prior docetaxel for various FACT-P metrics. Significant associations were seen between OS and FACT-P total score at baseline or change from baseline regardless of prior docetaxel use. Every 10-point increase in FACT-P total score from baseline (ie, improvement) was associated with an 18-21% decreased risk of death. FACT-P subscale results were similar, except social well-being. (Table) .
CONCLUSIONS: Improvement in HRQoL was associated with better OS in ALSYMPCA patients with metastatic castration-resistant prostate cancer regardless of prior docetaxel treatment.
Source of Funding: Bayer HealthCare
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ANDROGEN-DEPRIVATION THERAPY AND CARDIOVASCULAR RISK (ADTCR): A NATIONWIDE POPULATION-BASED COHORT STUDY
INTRODUCTION AND OBJECTIVES: Background. Observational studies suggested that androgen deprivation therapy (ADT) is associated with an increased cardiovascular (CV) risk. They all compared ADT-treated cancer patients to non-treated patients or noncancer subjects and there has not been to date a single trial with CV harm as a primary end point. Objective. To evaluate whether CV risk differs by type of ADT.
METHODS: Design. Through nationwide population-based claims reimbursement database linked to hospital discharge database, we identified adult men with prostate cancer who initiated ADT (GnRH agonist or antagonist, antiandrogen [AA], combined androgen blockade [CAB]) or had orchiectomy (OT) between 1st July 2010 and the 31st December 2011, and followed them up to 31st December 2013. Outcome measurements and statistical analysis. The main analysis followed an 'on-treatment' approach that censored all patients at the Vol. 197, No. 4S, Supplement, Sunday, May 14, 2017 THE JOURNAL OF UROLOGY â e767 time of first therapeutic modification; it used Cox regression analysis to estimate hazard ratios (HR) for hospitalizations for ischemic events (myocardial infarction or ischemic stroke, whichever came first), adjusted on age, baseline co-morbidities and taking into account death as a competing risk INTRODUCTION AND OBJECTIVES: Androgen deprivation therapy (ADT) plays an important role in managing prostate cancer, both as a primary treatment for metastatic disease and as a useful adjunct to radiotherapy or surgery with curative intent. However, some reports showed that ADT significantly increased cardiovascular risk. It has also been proposed that gonadotrophin-releasing hormone (GnRH) agonist may have negative effects on cardiac function at the receptor level. At present, little is known as to whether or not short-term ADT affects cardiac function. Brain-type natriuretic peptide (BNP) is in widespread use as a cardiac marker that can identify the risk of cardiovascular events. In order to assess the adverse impact of short-term ADT on cardiac function, we evaluated the change in BNP levels in patients undergoing radical prostatectomy (RP) with or without preoperative ADT.
METHODS: Between 2014 and 2016, 112 Japanese patients underwent RP in our hospital. Of them, 64 patients whose BNP levels were available and who had no prior cardiovascular disease were included in this retrospective study. BNP levels were evaluated before prostate biopsy and before RP. In this cohort, 31 patients received ADT preoperatively by combined androgen blockade using GnRH agonist and bicalutamide (ADT group), and the other 33 patients underwent RP without ADT (control group). The change in BNP levels was assessed in each group.
RESULTS: The median age and initial PSA level were 68 years and 8.8 ng/ml, respectively. No patients newly developed cardiovascular events during the study period. There were no significant differences between the two groups in age, body mass index, serum testosterone level, and comorbidities such as hypertension, diabetes, and dyslipidemia. The median BNP level before prostate biopsy was 13.9 pg/ml in the ADT group and 12.1 pg/ml in the control group (p ¼ 0.73). The median interval between evaluations of the BNP level was 12 (range 9-26) months in the ADT group and 6 (range 1-9) months in the control group. The median duration of ADT in the ADT group was 12 (range 8-25) months. In the ADT group, the median BNP level after ADT was 23.1 pg/ml, which was significantly higher than that before ADT (p < 0.01). In the control group, the median BNP level before RP was 12.8 pg/ml, showing no significant change from that before prostate biopsy (p ¼ 0.54).
CONCLUSIONS: The current study demonstrated a significant increase in BNP levels after short-term ADT in patients with prostate cancer, which might reflect the adverse impact of ADT on cardiac function. Recent data suggests that LHRH-antagonist may be associated with lower risk of these events compared to LHRHagonist. Our laboratory data suggest a role for FSH in mediating ADT induced atherosclerosis. We now report our early cardio-vascular outcome and change in FSH levels from a pilot randomized controlled study.
Source of
METHODS: A bicenteral randomized open-label study of the use of Degarelix compared to LHRH agonists among prostate cancer patients with pre-existing cardiovascular disease with scheduled to start ADT for at least a year. A Cardiovascular event was considered one of the following: myocardial infarction, ischaemic or haemorrhagic cerebrovascular event, arterial embolic and thrombotic events, emergency room visit or hospitalization due to ischaemic heart disease conditions, coronary artery or iliofemoral artery revascularization (percutaneous or surgical procedures), peripheral vascular disease event (vascular surgery/intervention). These events were prospectively collected. Serum levels for hormonal profile were taken at baseline and every three months.
RESULTS: Forty six patients were enrolled (23 randomized to each arm), with a median follow up of 6.3 months. No difference in age, stage of prostate cancer and baseline cardiovascular were observed between the two arms. During follow-up six patients developed a new cardio-vascular event. Four of the six patients were hospitalized due to ischemic heart disease, one patient suffered from a myocardial infarction and one from a new ischemic cerebrovascular event. All six patients were randomized to the LHRH-agonist arm of the trial (26%). None of the patients randomized to the Degarelix arm experienced any new cardio-vascular event during follow-up. All patients achieved castrate testosterone levels. FSH decreased from pre-ADT levels by a median of 93% among the Degarelix arm compared to 27% reduction in the agonist arm (p¼0.00011). Within the agonist arm, patients with a lower than 30% FSH decrease had a 50% probability of a cardiovascular event, compared to only 12.5% of patients with a higher effect on FSH levels.
CONCLUSIONS: Our pilot study suggests that cardio-vascular events may develop early in patients receiving LHRH-agonist compared to antagonist. These events may be linked to reduce suppression of FSH during ADT.
Source of Funding: Clinical trial was funded by Ferring Pharmaceuticals inc. Company does not have access to data.
